Clinical Governance in Obstetric Practice

The question of the prevention of pathologies of the labor is currently very important, the answer to them has become the favored formation of «dominants of delivery», choice of the optimal time to delivery, effective and safe method of induction, that promotes the promptness of the female organism and ripening of the cervix, as well as the timely identification and correction of pathological prelмmмnary period. In a review article describes the modern approaches and methods of preventing the pathology of labor activity, presented by the authors ‘ own experience regarding the use of prostaglandins, non-steroidal anti-inflammatory drugs, individual approach to the management of perinatal risk. Key words: childbirth, prevention, induction, prostaglandin, non-steroidal anti-inflammatory drugs.

Download Full-text

The experience of the Magnefar B6 application in obstetric practice

HEALTH OF WOMAN ◽

10.15574/hw.2019.137.82 ◽

2018 ◽

pp. 82-86

Author(s):

O.A. Dyndar ◽

Keyword(s):

Obstetric Practice

Download Full-text

Thromboembolic complications prevention in the obstetric practice

HEALTH OF WOMAN ◽

10.15574/hw.2017.117.19 ◽

2017 ◽

pp. 19-24

Author(s):

O.V. Grishchenko ◽

◽

V.V. Bobrytska ◽

Keyword(s):

Pulmonary Embolism ◽

Comparison Group ◽

Main Group ◽

Control Group ◽

Efficacy And Safety ◽

Thromboembolic Complications ◽

Moderate Risk ◽

Obstetric Practice ◽

Thrombotic Complications ◽

And Control

The objective: To evaluate the clinical efficacy and safety of Enoxaparin-Pharmex for the prevention of thrombotic complications (pulmonary embolism) in the postoperative period in patients with moderate risk of these complications. Patients and methods. The study included 50 women after a caesarean section had an average degree of risk of pulmonary embolism. Patients were divided into the main group (n=25) and control group (n=25) in accordance with the treatment: patients of the main group received postoperative Еnoxaparin- Pharmex, group comparisons enoxaparin sodium (brand foreign manufacturer’s). Patients in both groups received the drug at a dose of 20 mg for 5 days, 1 time per day subcutaneously. Results. The research data analysis showed identity results of hemostasiogram of patients in the main group and the comparison group, no side effects after treatment in both groups. Conclusion. The clinical studies suggest the drug Enoxaparin-Pharmex is effective, safe LMWH, which can be used to prevent troboembolic complications, including post-operative treatment in obstetric practice. Spectrum of Enoxaparin-Pharmex can be extended to the prevention and treatment of thromboembolic conditions of varying severity with appropriate doses of the drug. Key words: Enoxaparin-Pharmex, prevention of pulmonary embolism.

Download Full-text

Аcute diarrhea in obstetric practice

GYNECOLOGY ◽

10.26442/2079-5831_16.2.82-84 ◽

2014 ◽

Vol 16 (2) ◽

pp. 82-84

Author(s):

Yu.B. Uspenskaya ◽

Keyword(s):

Obstetric Practice

Download Full-text

Clinical governance in Australia

Clinical Governance An International Journal ◽

10.1108/cgij-03-2015-0008 ◽

2015 ◽

Vol 20 (2) ◽

pp. 56-73 ◽

Cited By ~ 6

Author(s):

Allan D Spigelman ◽

Shane Rendalls

Keyword(s):

Web Sites ◽

Service Providers ◽

Service Level ◽

Clinical Governance ◽

Success Factor ◽

Quality And Safety ◽

Funding Policy ◽

Content Type ◽

Health Service Providers ◽

Governance Systems

Purpose – The purpose of this paper is to overview, background and context to clinical governance in Australia, areas for further development and potential learnings for other jurisdictions. Design/methodology/approach – Commentary; non-systematic review of clinical governance literature; review of web sites for national, state and territory health departments, quality and safety organisations, and clinical colleges in Australia. Findings – Clinical governance in Australia shows variation across jurisdictions, reflective of a fragmented health system with responsibility for funding, policy and service provision being divided between levels of government and across service streams. The mechanisms in place to protect and engage with consumers thus varies according to where one lives. Information on quality and safety outcomes also varies; is difficult to find and often does not drill down to a service level useful for informing consumer treatment decisions. Organisational stability was identified as a key success factor in realising and maintaining the cultural shift to deliver ongoing quality. Research limitations/implications – Comparison of quality indicators with clinical governance systems and processes at a hospital level will provide a more detailed understanding of components most influencing quality outcomes. Practical implications – The information reported will assist health service providers to improve information and processes to engage with consumers and build further transparency and accountability. Originality/value – In this paper the authors have included an in depth profile of the background and context for the current state of clinical governance in Australia. The authors expect the detail provided will be of use to the international reader unfamiliar with the nuances of the Australian Healthcare System. Other studies (e.g. Russell and Dawda, 2013; Phillips et al., n.d.) have been based on deep professional understanding of clinical governance in appraising and reporting on initaitives and structures. This review has utilised resources available to an informed consumer seeking to understand the quality and safety of health services.

Download Full-text